Flow Cytometric Immunophenotyping Distinguishes Lymphoplasmacytic Lymphoma from Marginal Zone Lymphoma
Authors: Choong Shi Hui Clarice , Chng Wee-Joo , De Mel Sanjay , Liu Te-Chih , Li Bei Jenny , Poon Li Mei Michelle , Lee Shir Ying , Tae Hoon Chung , Teng Rebecca , Chan Seok Wei Stephrene 
Published: November 2019

Introduction:

Flow cytometric (FC) immunophenotyping is an essential tool for the diagnosis of mature B cell lympho-proliferative disorders (B-LPDs). The most common CD5-negative/CD10-negative B-LPDs are hairy cell leukemia, lymphoplasmacytic lymphoma and marginal zone lymphoma. Although HCL has unique clinicopathologic characteristics, LPL and MZL are often difficult to distinguish by standard diagnostic methods. MYD88 L265P mutations are found in 90% of LPL and 8-10% of MZL, although the finding of this mutation may increase the suspicion of LPL, it is by no means definitive since they are also found in MZL. The distinction between LPL and MZL is of increasing clinical importance given treatment options and prognosis may differ. The Euroflow eight color B-LPD panel provides detailed information on the phenotype of clonal B-cells and has not previously been evaluated as a tool to distinguish these subtypes of B-LPD.

Methods:

A retrospective study of patients who were diagnosed with CD5-negative/CD10-negative B-LPD from January 2011 to October 2017 was conducted. Patients with HCL and diffuse large B cell lymphoma were excluded. Data collected included the FC immunophenotype, clinical findings, MYD88 mutational status, treatment and outcome. Data were obtained from the FC lab database at the National University Health System (NUHS) Hematology laboratory. Clinical data were obtained from the electronic patient medical records. A clinicopathologic diagnosis of either LPL, MZL or "indeterminate between LPL/MZL" was assigned to the patients based on consensus at the multidisciplinary tumor board. The FC phenotype (based on raw median fluorescence intensity values) of patients assigned to each diagnostic category were then compared. Hierarchical clustering using Gower's distance of variables and Ward's D linkage method were used to determine if the FC immunophenotyping patterns can distinguish LPL and MZL.

Results:

A total of 22 patients' data was included in the analysis. We found that the LPL cases formed a discrete cluster, while MZL cases were more widely dispersed (figure 1). LPL cases showed negative expression of CD 39, CD 43 and CD 95, while these markers are expressed in a significant proportion of MZL cases. In contrast, CD31 was expressed in the majority of LPL but not the MZL cases. CD 200 and CD38 were found to be variably expressed in both LPL and MZL cases. It is noteworthy that CD 27 was also not consistently expressed across all the cases in our study. There were also no significant differences in terms of surface IgM expression.

Conclusions:

Our study showed that the eight color flow cytometry has potential as a tool to differentiate LPL and MZL. The lack of a discrete clustering of the MZL cases in our analysis may be explained by the fact that MZL is a more heterogeneous entity compared to LPL. Positivity for CD31 and negativity for CD39, CD95 and CD43 appear to be features of LPL. MZL in contrast show positive expression of CD39, CD95 and CD43 and are negative for CD31. Earlier studies using four color FC suggested that CD200 may have value as a discriminative marker between LPL and MZL. Our data using eight color FC does not show the same discriminative power for CD200. The absence of consistent CD39 and CD27 expression is unusual as LPL and MZL are both post germinal centre B cell neoplasms in which the expression of these antigens is expected. We propose that FC immunophenotyping should be evaluated prospectively as an adjunct to standard clinicopathologic evaluation to distinguish LPL and MZL.

Figure 1

Disclosures

No relevant conflicts of interest to declare.